



MICROCOPY RESOLUTION TEST CHART NATIONAL BUREAU OF STANDARDS-1963-A

}\_\_\_



# SYNTHESIS OF C-5 SUBSTITUTED TUBERCIDIN DERIVATIVES

Annual Progress Report

Donald E. Bergstrom

(for the period 1 February 1979 to 31 January 1980)

Supported by

U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, Maryland

Contract No. DAMD-17-78-C-8014

University of California Davis, California 95616

FILE COPY

Approved for public release; distribution unlimited



 $\hat{\mathbf{x}}$ 

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

83 04 11 075

REPORT DOCUMENTATION PAGE	READ INSTRUCTIONS
I. REPORT NUMBER 2. DURCESSON	RECIPIENT'S CATALOG NUMBER
HILL GO	
. TITLE (and Subtitie)	5. TYPE OF REPORT & PERIOD COVERED
	Annual Report
Synthesis of C-5 Substituted Tubercidin	(February 1979-January 1980)
Derivatives	6. PERFORMING ORG. REPORT NUMBER
· AUTHOR(e)	8. CONTRACT OR GRANT NUMBER(#)
Donald E. Bergstrom, Ph.D.	DAMD17-78-C-8014
PERFORMING ORGANIZATION NAME AND ADDRESS	10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
University of California	62770A. 3M162770A803.00.044
Davis, California 95616	
1. CONTROLLING OFFICE NAME AND ADDRESS	12. REPORT DATE
US Army Medical Research and Development Commany	January 1980
Fort Detrick	13. NUMBER OF PAGES
Frederick, Maryland 21701	24
14. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office,	15. SECURITY CLASS. (of this report)
	Unclassified
	154. DECLASSIFICATION DOWNGRADING
	SCREDULE
6. DISTRIBUTION STATEMENT (of this Report) Approved for public release; distribution unlim:	ited
6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim:	ited
6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the ebetrect entered in Block 20, if different	ited from Report)
6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the ebstrect entered in Block 20, if different	ited
6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the ebetrect entered in Block 20, if different	ited from Report)
6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the ebetrect entered in Block 20, if different	ited from Report)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report)</li> <li>Approved for public release; distribution unlim:</li> <li>7. DISTRIBUTION STATEMENT (of the ebetrect entered in Block 20, if different</li> <li>18. SUPPLEMENTARY NOTES</li> </ul>	ited from Report)
6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the ebetrect entered in Block 20, if different 18. SUPPLEMENTARY NOTES	ited from Report)
6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the ebetrect entered in Block 20, if different 18. SUPPLEMENTARY NOTES	ited from Report)
6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different 18. SUPPLEMENTARY NOTES	ited from Report)
<ol> <li>DISTRIBUTION STATEMENT (of the Report)         Approved for public release; distribution unlim:         Approved for public release; distribution unlim:         To an additional public release; distribution unlim:         To additin the relea</li></ol>	ited from Report)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if necessary and identify by block numb</li></ul>	ited from Report)
6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if necessary and identify by block numb	ited from Report)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim:</li> <li>7. DISTRIBUTION STATEMENT (of the abetract entered in Block 20, if different</li> <li>18. SUPPLEMENTARY NOTES</li> <li>9. KEY WORDS (Continue on reverse eide if necessary and identify by block numb</li> </ul>	ited from Report)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim:</li> <li>7. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different</li> <li>18. SUPPLEMENTARY NOTES</li> <li>9. KEY WORDS (Continue on reverse eide if necessary and identify by block numb</li> <li>6. ABSTRACT (Continue on reverse eide N mec-seary and identify by block number</li> </ul>	ited (rom Report) er)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: </li> <li>7. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different IB. SUPPLEMENTARY NOTES </li> <li>9. KEY WORDS (Continue on reverse eide if necessary and identify by block numbers) ABSTRACT (Continue on reverse eide N mec-seary and identify by block number) </li> </ul>	ited from Report) er)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the abetract entered in Block 20, if different 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse eide if necessary and identify by block numbe 9. KEY WORDS (Continue on reverse eide if necessary and identify by block numbe 9. ABSTRACT (Continue on reverse eide if necessary and identify by block numbe</li></ul>	ited from Report) er)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: </li> <li>7. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different IS. SUPPLEMENTARY NOTES </li> <li>9. KEY WORDS (Continue on reverse elde if necessary and identify by block numbe ABSTRACT (Continue on reverse elde if necessary and identify by block numbe) </li> </ul>	ited from Report)  er)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: </li> <li>7. DISTRIBUTION STATEMENT (of the ebetrect entered in Block 30, if different IB. SUPPLEMENTARY NOTES </li> <li>9. KEY WORDS (Continue on reverse eide if necessary and identify by block numbe ABSTRACT (Continue on reverse eide N mechanisty and identify by block numbe) ABSTRACT (Continue on reverse eide N mechanisty and identify by block numbe)</li></ul>	ited from Report) er) er)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: </li> <li>7. DISTRIBUTION STATEMENT (of the ebetrect entered in Block 20, if different II. SUPPLEMENTARY NOTES </li> <li>9. KEY WORDS (Continue on reverse eide II necessary and identify by block numbe ABSTRACT (Continue on reverse eide N mer-veary and identify by block numbe) </li> </ul>	ited from Report)
<ul> <li>6. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlim: 7. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different 18. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse elde if necessary and identify by block numb 6. ABSTRACT (Continue on reverse elde N necessary and identify by block numbe</li></ul>	ited from Report) er)

SECURITY CLASSIFICATION OF THIS PAGE (When Date Entered)

-----

いと数

.....

....

States and the second states and the

## Abstract

C-5 substituted pyrrolo (2,3-d) pyrimidine nucleosides were synthesized via reactions of 5-mercuritubercidin (2). Palladium catalyzed carbonylation of 2 in methanol gave 5-methoxycarbonyltubercidin (5) which could be converted to the nucleoside antibiotic sangivanycin (6) by reaction with ammonia. Reduction of 5 with LiBH, in tetrahydrofuran gave 5-hydroxymethyltubercidin (7). Longer carbon chains were introduced by the palladium catalyzed coupling of olefins with mercuritubercidin. 5-Mercuritubercidin and methyl acrylate in 0.1 M Li<sub>2</sub>PdCl, in methanol gave (E)-5-(2-methoxycarbonylethenyl)tubercidin <math>(3)which on treatment with aqueous sodium hydroxide was hydrolyzed to (E)-5-(2carboxyethenyl)tubercidin (8). Nucleoside 8 was converted to (E)-5-(2-bromoethenyl)tubercidin 9 by N-bromosuccinimide in N,N-dimethylformamide.

3-Chloro-1-butene reacted with 2 and  $\text{Li}_2\text{PdCl}_4$  to give a mixture of E and Z 5-(2-buten-1-yl)tubercidin (13,14). Styrene coupled with 2 to give 5-styryltubercidin 12. Finally the mercury could be replaced directly by iodine in DMF to give 5-iodotubercidin (15).

Characterization of the C-5 substituted tubercidin derivatives by  $^{1\,3}\mathrm{C}$  NMR is discussed. ,

Acces	sion For		
NTIS	GRA&I	X	
DTIC	TAB		
Unann			
Justi	fication_		
By Distr	ibution/		
Avai	lability	Codes	્રો
Dist	Avail and Special	i/or	÷.
Pt		,	

# TABLE OF CONTENTS

1

.

			Page		
I.	Int	roduction	4		
11.	Syn	thetic Studies	7		
	Α.	Synthesis and Reactions of 5-Methoxycarbonyl- tubercidin	7		
	в.	Synthesis of 5-(2-Bromoetheny1)tubercidin	9		
	с.	Reduction of $(\underline{E})$ -5-(2-Cyanoethenyl)tubercidin	10		
	D.	$(\underline{E})$ -5-(2-Phenylethenyl)tubercidin	10		
	Ε.	Reaction of 5-Mercuritubercidin with 3-Chloro-l-butene	10		
	F.	Iodination of 5-Mercuritubercidin	10		
III.	Spe	ctroscopic Characterization	12		
IV.	IV. List of Compounds Submitted for Biological Testing (Table III)				
۷.	Exp	erimental Section	16		
Refere	nces		20		

#### I. Introduction

The major objective of our research program is the synthesis of a series of tubercidin derivatives which vary structurally in the C-5 side chain. The parent compound, tubercidin (1), is an effective agent against <u>Schistosoma mansoni</u> and <u>S. japonium</u>, but is too toxic to man unless administered intraerythrocytically.<sup>1,2</sup> On the basis of the biochemical properties and biological activity of tubercidin and the few known examples of C-5 modified derivatives of tubercidin, there is reason to be optimistic about finding significant biological activity from other examples of this class of compounds. Selective activity toward protozoan and helminthic parasites may possibly be achieved on the basis of certain biochemical differences between the parasites and mammalian cells. The former require exogenous purine and purine nucleosides while most mammalian cells can synthesize the purine ring de novo. Consequently adenosine metabolizing enzymes and the transport system in parasites may differ enough from the corresponding enzymes and transport system in mammalian cells to provide selective targets for nucleoside antagonists.

In our previous annual report (for the period 1 February 1978 to 31 January 1979) we reported development of new methodology for the synthesis of C-5 substituted derivatives of tubercidin (1).

Mercuration of tubercidin by mercuric acetate in aqueous solution gave a white polymeric product which on the basis of <sup>1</sup>H NMR spectroscopy and elemental analysis was proposed to have structure  $2.^{3}$ 



Mercuritubercidin (2) reacts with olefins and lithium palladium chloride in methanol solution leading to a C-5 coupled product. For example the organopalladium intermediate (1) derived from 2 couples with methyl acrylate to give principally 5-(2-methoxycarbonylethenyl)tubercidin (Scheme I).



-HPdC1



Ŕ

iv







-5-

Although no mechanistic studies were done in this instance the schemes proposed by Heck<sup>4</sup> for the reaction of phenylmercuric acetate with propylene and Pd(II) in methanol and acetonitrile and the results of our studies<sup>5</sup> on the reaction of 5-chloromercuri-2'-deoxyuridine with propylene and Pd(II) lead us to propose the pathway shown in Scheme I. The mercuritubercidin complex 2 must undergo metal-metal exchange with palladium chloride or the methyl acrylate - palladium chloride  $\pi$ -complex to give intermediate <u>i</u>. Insertion of methyl acrylate into the Pd-C  $\sigma$  bond proceeds regioselectively to give <u>ii</u> which through cis elimination of Pd-H leads to the  $\pi$ -complex <u>iii</u>.

The predominant pathway involves dissociation of  $\pi$ -complex <u>iii</u> to give Pd(0), HCl, and nucleoside 3. However <u>iii</u> may be in equilibrium with both <u>ii</u> and <u>iv</u>. Intermediate <u>iv</u>, unlike <u>ii</u>, could dissociate with loss of Pd(0) to a stabilized carbocation, <u>v</u>, which would be expected react with the most readily available source of nucleophile, methanol, to give nucleoside 4. The reaction of ethylene with 5-chloromercuriuridine and Li<sub>2</sub>PdCl<sub>4</sub> in MeOD previously established the occurrence of a palladium-mediated intramolecular hydride shift<sup>5</sup> as postulated here for the interconversion of intermediates ii and iv.

The trans stereochemistry of 3 is presumed on the basis of the 16 Hz coupling constant between the olefinic protons. In this and all other coupling reactions to olefins of structure  $CH_2=CHY$  where Y is a group capable of conjugation, the isolated products have shown only trans stereochemistry.

All of the coupling reactions previously discussed probably follow this same pathway. C-5 substituted tubercidin derivatives for which experimental details were given in the progress report for 1978 are listed in Table I.

Table I. Tubercidin Derivatives Synthesized in 1978

5-(1-Methoxyethy1)tubercidin

5-(1-Hydroxyethy1)tubercidin

5-(1-Isopropoxyethyl)tubercidin

5-Allyltubercidin

5-Mercuri-2',3'-0-isopropylidene tubercidin

5-(2-Cyanoetheny1)tubercidin

5-(2-Carboxamidoetheny1)tubercidin

5-(2-Carbomethoxyethenyl)tubercidin

5-(2-Carbomethoxyethyl)tubercidin

Not all of these derivatives could be completely characterized. For example 5-allyltubercidin was obtained from 2,  $\text{Li}_2\text{PdCl}_4$ , and allyl chloride in low yield along with many side products. It was never purified to an acceptable extent. Consequently during 1979, the reaction between 2 and 3-chloro-1-butene was investigated more fully to finally establish whether allylic chlorides could be coupled successfully to tubercidin.

Finally, one major advance in the research project during 1979, was the discovery that carbon monoxide could be coupled to mercuritubercidin (2) in methanol to give the versatile synthetic intermediate 5-methoxycarbonyltubercidin. This now appears to be the most straightforward route to introduce the single carbon unit at C-5.

The results of biological testing have arrived sporatically and will not be discussed in the present report but in a final report to appear in July, 1980.

## II. Synthetic Studies

### A. Synthesis and Reactions of 5-Methoxycarbonyltubercidin

A straightforward route for the introduction of a single carbon unit at C-5 of tubercidin is particularly desirable. Not only do the nucleoside antibiotics, sangivamycin and toyocamycin, have a one carbon functional group at this position, but the hypermodified t-RNA bases, Nucleoside Q and Q\*, have a methylene group at C-5 of a pyrrolo[2,3-d]pyrimidine nucleus.<sup>6</sup>,<sup>7</sup> We have found it possible to introduce a one carbon functional group at C-5 in oxidation states characteristic of both classes of compounds. The key reaction is the palladium catalyzed carbonylation reaction first developed by P. M. Henry.<sup>8</sup> Aryl mercuric chlorides react at room temperature with carbon monoxide and palladium chloride in acetic acid to give carboxylic acids. In methanol solvent, the product is a methyl ester. R. F. Heck<sup>9</sup> and R. C. Laroch<sup>10</sup> have explored and greatly expanded the scope of the reaction.

When mercuritubercidin and lithium palladium chloride were combined in methanol under a carbon monoxide atmosphere slow conversion to 5-methoxycarbonyltubercidin (5) occurred (Scheme II). The yield was not high (24% after purification) but the method is both direct and simple. The methoxycarbonyl group can be further converted to other functional groups without protection of the 4-amino or sugar hydroxyls. Ammonolysis in aqueous ammonium chloride - ammonium hydroxide gave the nucleoside antibiotic sangivamycin (6). The only previous synthesis of 6 involved reaction of 5-cyano-6-bromotubercidin with ammonium hydroxide in 30% H<sub>2</sub>O<sub>2</sub> followed by catalytic hydrogenolysis of the 6-bromo group.<sup>15</sup> Reduction of 5 with lithium borohydride in refluxing THF gave 5-hydroxymethyltubercidin (7).

-7-

Scheme II



-8-

## B. Synthesis of 5-(2-Bromoethenyl)tubercidin

Nucleoside 3 has proved to be a versatile intermediate. We previously demonstrated that the carbon-carbon double bond could be selectively reduced. We also have been able to reduce the side chain completely to give 5-(3-hydroxypropyl)tubercidin, but experimental details have not yet been completely worked out so this reaction will be reported at a later date. Perhaps more interesting from the synthetic chemist's viewpoint is the transformation of 3 to (E)-5-(2-bromoethenyl)tubercidin (Scheme III). Jones et al<sup>11</sup> demonstrated that (E)-5-(2-carboxyvinyl)pyrimidine nucleosides could be decarboxylated and brominated by NBS in hot aqueous solution to give (E)-5-(2-bromovinyl)nucleosides in good yield. (E)-5-(2-Carboxyethenyl)tubercidin (8), prepared by hydroxide catalyzed hydrolysis of 3, did not react to give identifiable products with NBS in water but in DMF gave (E)-5-(2-bromoethenyl)tubercidin (9) in 26% yield. The 15 Hz coupling constant between the olefinic protons confirmed that the trans stereochemistry was retained.

Scheme III



-9-

# C. Reduction of (E)-5-(2-Cyanoethenyl)tubercidin

A number of attempts have been made to reduce the cyanoethenyl group of 10 (Scheme III) to a 3-aminopropyl side chain. Reducing conditions known to transform the cyano function to amines have given anomolous results with either nucleosides 10 or 11. Reduction of 10 by H<sub>2</sub> at low pressure in neutral solution over 10%  $\widetilde{Pd}/C$  cleanly reduces 10 to 5-(2cyanoethyl)tubercidin (11). When the reduction was carried out in dilute HCl, further reduction was evident but 5-(3-aminopropyl)tubercidin could not be isolated. Neither could this reduction be achieved by NaBH<sub>4</sub>-CoCl<sub>2</sub> or by AlH<sub>3</sub>.

### D. (E)-5-(2-Phenylethenyl)tubercidin

The reaction of mercuritubercidin with styrene and  $Li_2PdCl_4$  has only recently given definitive results. Like the reaction with mercuripyrimidine nucleosides the coupling proceeds regioselectively. Howe or the tubercidin reaction gives many minor side products and a signif . tly lower yield of the desired product.

Coupling in methanolic 0.1 <u>M</u> Li<sub>2</sub>PdCl<sub>4</sub> gave (E)-5-(2-phenylethe )tubercidin (12) in 25% yield (Scheme IV). Unlike (E)-5-(2-phenylet )uridine<sup>5</sup>, 12 was not appreciably fluorescent. The trans stereochen was established by <sup>1</sup>H NMR at 360 MHz. At this high field the olefin. protons were clearly separated (7.01 and 7.54 ppm) and showed a 16.05 Hz coupling constant.

### E. Reaction of 5-Mercuritubercidin with 3-Chloro-1-butene

Like 2'-deoxyuridine<sup>12</sup>, mercuritubercidin, 2, gave both (E) and (Z) isomers on coupling with 3-chloro-1-butene (Scheme IV). The isomers, 13 and 14, could not be separated by either TLC or HPLC on an analytical C-18 reverse phase column. However, their identity and relative yield was clearly established by <sup>13</sup>C NMR of the mixture. Perhaps most encouraging is the contrast between the coupling reactions of 3-chloro-1-butene and ally1 chloride. The former proceeds significantly more cleanly.

Studies on 5-mercuri-2'-deoxyuridine clearly  $show^{12}$  that longer chain allylic chlorides couple as rapidly as 3-chloro-1-butene and give only a single product, the (E) isomer. Consequently, in the future this may prove the most efficient pathway for introducing aliphatic side chains at C-5 of tubercidin.

#### F. Iodination of 5-Mercuritubercidin

Finally the halogenation of mercuritubercidin was investigated in the interest of developing a short route to 5-chloro-, 5-bromo- and 5-iodotubercidin. All exhibit significant biological activity, but in particular 5-bromotubercidin was demonstrated to be an <u>in vivo</u> reversible inhibitor of RNA synthesis<sup>13</sup> and 5-iodotubercidin (15) a potent inhibitor of adenosine kinase.<sup>14</sup> The halogenation of mercuritubercidin (2) was not anticipated to be a problem in light of the successful halogenation of Scheme IV



÷

.





15 ~~

-11-

5-mercuripyrimidine nucleotides.<sup>15</sup> Iodination by  $I_2$  in methanol-water, DMF, or HMPA proceeded smoothly but purification of the product was difficult because of the insolubility of 15 in water (neutral, acidic, or basic) and organic solvents with the exception of HMPA and methanol (sparingly soluble). Elimination of all traces of mercuric iodide was especially tedious. Column chromatography on silica gel eluting with methanol-chloroform resulted in substantial loss of material but the purity was now sufficient for recrystallization from methanol. A minor product which separated but could never be purified was assigned the structure 5,6-diiodotubercidin on the basis of the resemblance of its <sup>1</sup>H NMR spectrum to that for 5,6-dibromotubercidin. Approximately ten percent diiodination was anticipated on the basis of the structure of 2. Bromination of 2 with either  $Br_2$ , NBS, or  $CuBr_2$  in methanol, water, or DMF gave complex mixtures of products of which 5-bromotubercidin was a major (but overall low yield) constituent.

#### III. Spectroscopic Characterization

The majority of synthetic compounds described here and in previous reports were characterized by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and elemental analysis. <sup>13</sup>C NMR has provided the most reliable data for making structure assignments (Table II). Chenon et al<sup>16</sup> have established carbon chemical-shifts for the naturally occurring pyrrolo[2,3-d]pyrimidine nucleosides. Like these authors we have determined <sup>13</sup>C NMR spectra with complete proton decoupling. Our data on a large number of C-5 substituted compounds (Table II) confirms the observations made by Chenon et al. The chemical shifts of the ribosyl carbons are for the most part invariant and unaffected by the structure of the C-5 substituent. The only heterocycle carbon shifts significantly dependent on C-5 substitution are C-5 and C-6. Comparison of nucleosides 1, 5-7, and toyocamycin (5-cyanotubercidin) are illustrative. The carbon signals for C-2, C-4, C-4a, and C-7a fall within a 2 ppm range while those at C-5 vary from 83.2  $ppm^{16}$  for toyocamycin to 115.5 ppm for 5-hydroxymethyltubercidin (7), and at C-6 from 119.1 for 5 to 132.6 for toyocamycin The relative magnitude and direction of the shifts parallels those observed in derivatives of benzene.<sup>17</sup> For example, both C-1 and C-2 of methyl benzoate are shifted downfield (2 ppm and 1.2 ppm respectively) from the carbon signal for benzene (128.5 ppm). The C-5 and C-6 resonances of 5-methoxycarbonyltubercidin (5) are shifted 6.5 and 7.0 ppm downfield respectively from the signals observed in tubercidin. In contrast, the C-1 and C-2 signals of benzyl alcohol fall at 141.0 and 126.9 ppm respectively. These values represent shifts of 12.5 ppm downfield for C-1 and 1.6 ppm upfield for C-2. The corresponding carbons in 5-hydroxymethyltubercidin show parallel shifts with respect to tubercidin. The C-5 resonance of 7 is shifted 16 ppm downfield while the C-6 resonance falls 3.2 ppm further upfield. Other tubercidin derivatives have also shown parallel and consistent results in comparison to <sup>13</sup>C NMR data on simpler model compounds.



Table II. <sup>13</sup>C NMR Spectra <sup>a</sup>

Nucleoside	C-5 Substituent	C-2	C-4	C-4a	C-5	C-6	<u>C-7a</u>
1	H	151.5	157.5	103.1	99.5	122.3	149.9
<u>6</u>	CONHS	152.69	157.95		110.85	125.90	150.82
5	CO <sub>2</sub> Me	153.75	157.49	100.48	106.06	129.26	151.08
7	сн <sub>г</sub> он	151.26	157.23	102.62	115.54	119.06	151.06
3	CH=CHCO2He	151.50	157.38		110.49	123.65	151.10
4	OHE CHCH <sub>2</sub> CO <sub>2</sub> Me CH=CHCONH <sub>2</sub>	152.23 151.57	154.84 157.27	102.05 100.79	115.40 111.47	122.17 122.78	151.06 150.90
10	CH=CHCN	152.35	157.94	100.11	92.52	122.94	151.32
8~	ch=chco <sub>2</sub> h	150.05	154.04	100.55	112.16	124.74	147.04
<u>9</u>	CH=CHBr	151.01	156.86	100.12	111,22	119.74	150.88
	CH2CH2CO2Me	150.48	156.67	101.24	112.62	118.69	149.82
11	CH2CH2CN	151.26	157.26	101.82	111.78	120.10	150.55
	OMe CHCH <sub>3</sub> a	152.43	158.35	103.56	120.20	123.03	151.98
	СНСН3	150.27	156.03	101.71	119.24	121.71	149.26
12 22	CH=CH-	151.40	157.61	100.88	113.83	120.26	150.79
13,14	(E)&(Z) CH <sub>2</sub> CH=CHCH <sub>3</sub>	151.73	157.74	102.92	114.32	120.53 120.05	151.06
15	1	151.76	156.91			127.05	150.02

<sup>a</sup> All spectra were run in 6-d DMSO and are referenced to external TMS.

<u>C-1'</u>	<u>C-2'</u>	C-3'	C-4'	<u>C-5'</u>	<u>C-1"</u>	<u>C-2"</u>	C-3"	C-4"	C-5"
87.6	73.7	70.8	85.1	61.9					
86.96	72.32	70.50	85.25	61.72	166.17				
87.48	74.03	70.23	85.84	61.12	165.17		-0 <u>C</u> H3	51.80	
87.14	73.73	70.81	85.13	61.97	56.43				
86.97	73.78	70.29	85.03	61.49	136.39	115.06	166.27	-0 <u>C</u> H3	51.15
									<b>FF</b> 00
87.60	73.95	71.08	85.41	62.0	73.95	42.37	174.96	- <u>OCH</u> 3	55.90 52.73
86.96	73.85	70.57	85.20	61.66	130.64	121.11	167.16		
87.00	73.72	70.29	85.07	61.52	142.58	110.72	119.00		
87.88	74.47	70.44	85.68	61.49	135.53	118.95	167.82		
86.83	73.55	70.26	84.95	61.49	128.58	104.93			
86.17	72.63	69.74	84.00	60.93	20.45	33.86	171.94	-0 <u>C</u> H3	50.44
87.03	73.41	70.48	84.81	61.70	21.80	18.26		-	
89.39	75.65	72.79	86.90	63.92	74.71	23.58	-0 <u>C</u> H3	56.88	
87.20	74.19	70.99	85.47	61.97	62.73	25.34			
86.90	73.64	70.47	84.98	61.67	una	ssigned			
87.51	73.98	71.11	85.43	62.28	29.49 24.33	130.53 128.70	126.51 125.90	18.22 13.35	
86.62	73.67	70.26	85.01	61.30					

. .

-14-

ويحتو المعادين والمنادي

....

Table III. Compounds Submitted for Biological Testing

Structure No.	C-5 Substituent	Code No.	WRAIR No.	Date Rcd.
11	-CH2CH2CN	DEB-5	BJ30609	79/07/20
	OMe			
4 ~	-CHCH2CO2Me	DEB-6	BJ30618	79/07/20
	3-β- <u>D</u> -ribofuranosy1-2,7- dioxopyrido[2,3- <u>d</u> ]pyrimidine	DEB-7	BJ30627	79/07/20
	CH2CH2CO2Me	DEB+8	BJ36610	79/08/31
12 ~~	-CH=CHPh	DEB-9	BJ45351	79/12/26
7 ~	-сн <sub>2</sub> он	DEB-10	BJ45360	79/12/26
5~~	-C0 <sub>2</sub> Me	DEB-11	BJ45379	79/12/26

-15-

-

#### Experimental Section

٧.

Proton magnetic resonance spectra were taken on either a Varian EM360 60Mz instrument or a Fourier Transform NMR, Jeol Model PS100. Sodium 2,2,3,3-tetradeutero-3-(trimethylsilyl)propionate (TSP) was employed as the internal standard for spectra run in  $D_2O$  or  $d^6$ -DMSO. <sup>13</sup>C NMR spectra were obtained on the latter instrument. Infrared spectra were obtained on a Beckman IR-8 in solid KBr with a polystyrene standard. Ultraviolet spectra were measured on either a Cary 15 or Cary 17 spectometer. Melting points were taken on a Büchi 510 M.P. apparatus and are uncorrected. Elemental analyses were performed by Galbraith Labs or the Microanalytical Lab of UC Berkeley. Column chromatography was done on Bio-Gel P2 and E. Merck Silica Gel 60. Analytical thin layer chromatography (TLC) was carried out on E. Merck Precoated Silica Gel F-254 (0.25 mm) plastic-backed TLC sheets cut to 30 x 110 mm. The sheets were developed in the specified solvent systems in 12 cm high wide-mouth jars lined with filter paper. Solvent systems were: A, MeOH-CHCl<sub>3</sub> (1:3, v/v); B, AcCN-nBuOH-0.1 M NH<sub>4</sub>OAc-conc. NH<sub>4</sub>OH (10:60:20:10, v/v); C, MeOH-EtOAc (3:2, v/v); and others which will be specified. All solvents and reagents were reagent grade. Tubercidin was purchased from the Upjohn Company Fine Chemicals Division. Water was deionized and then distilled through glass. Coupling reactions with ethylene and hydrogenations were carried out in Parr bottles using an apparatus similar to that described by Barefield.<sup>18</sup> The apparatus was modified from the one described by the addition of a separate permanent connection adapted for easy exchange of lecture bottles.

For purposes of reference, tubercidin has the following properties: MP 247°C (dec); UV spectrum:  $\lambda_{max}^{272}$  ( $\epsilon = 12,200$ ) in .01 <u>M</u> HCl,  $\lambda_{max}^{270}$  (12,100) in .01 <u>M</u> NaOH.<sup>12</sup> IR (KBr): 3200 (br), 1600 (br), 1450, 1362, 1260, 1140, 1051, 1012, 912, 878 cm<sup>-1</sup>; TLC (solvent system/Rf value): A/.28, B/.43, C/.54; <sup>1</sup>H NMR (d<sup>6</sup>-DMSO):  $\delta$  8.18 (1H, s, H2), 7.45 (1H, d, J = 4Hz, H6), 7.17 (2H, s, NH<sub>2</sub>), 6.70 (1H, d, J = 4Hz, H5), 6.11 (1H, d, J = 6Hz, H1'), 4.55 (1H, mult., H4'), 4.1 (2H, mult., H2' and H3'), 3.6 (2H, mult., H5').

5-(Methoxycarbonyl)tubercidin (5). To a 250 ml Parr bottle were added 525 mg (0.946 mM) 5-acetoxymercuritubercidin and 20 ml of a methanolic 0.1 M Li<sub>2</sub>PdCl<sub>4</sub> solution (2 mM). The mixture was stirred under 35 psi carbon monoxide for three days at 25°C. The reaction mixture was filtered, saturated will hydrogen sulfide and refiltered. Neutralization with conc. NH<sub>4</sub>OH evaporation onto 3 g of silica gel and chromatography on 200 g silica gel using a chloroform-methanol gradient gave 77 mg (0.23 mM, 24%) of white crystalline product, mp 214.5-216°. The product exhibited a single component on TLC (silica gel; system A) and HPLC (C-18 reverse phase; 0.01 M NH<sub>4</sub>H<sub>2</sub>PO<sub>4</sub>, acetonitrile; 85:15, v/v). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  8.31 (s, 1H), 8.17 (s, 1H), 6.12 (d, 1H, J=6Hz), 4.44 (m, 1H), 4.0 (broad m, 2H), 3.83 (s, 3H), 3.62 (m, 2H). UV  $\lambda_{max}^{MeOH}$  276 nm, 229 nm.

Anal. Calcd. for  $C_{13}H_{16}N_{4}O_{6}$ : C, 48.15; H, 4.97; N, 17.28. Found: C, 48.02; H, 5.10; N, 17.10.

-16-

5-Carboxamidotubercidin (Sangivamycin) (6). 5-Methoxycarboyl-

tubercidin (5) (0.092 g, 0.284 mM) and ammonium chloride (0.82 g) dissolved in conc. ammonium hydroxide (15 mL) with warming. Once 5 was completely dissolved the mixture was cooled and allowed to stir at room temperature for seven hr. Evaporation to dryness in vacuo gave a white solid. Chromatography on silica gel eluting with a gradient of 15% to 40% methanol-chloroform gave 52 mg of 3 (Rf 0.15, system A). The <sup>13</sup>C NMR spectrum was virtually identical to that reported for sangivamycin by Chenan et al.<sup>19</sup>

5-Hydroxymethyltubercidin (7). 5-(Methoxycarbonyl)tubercidin

(1.246 g, 3.84 mM) in 70 ml dry THF was combined with 0.836 g (38 mM) LiBH4 and refluxed under an argon atmosphere for 20 hours. The reaction mixture was then evaporated four times with 10 ml portions of methanol containing about 5% HCl. The reaction mass was then taken up in methanol and neutralized with conc. NH4OH and evaporated with 7 g of silica gel. Chromatography on 300 g silica gel using a chloroform-methanol gradient afforded, after recrystallization from methanol, 518 mg (1.74 mM, 45%) of white crystalline product, mp 219-220.5°C. HPLC C-18 reverse phase; 0.01 M NH4H2PO4, acetonitrile; 92:8, v/v) and TLC (silica gel, system A) indicated a pure product. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  8.13 (s, 1H), 7.32 (s, 1H), 6.05 (d, 1H, J = 6Hz), 4.63 (s, 2H), 4.47 (m, 1H), 4.12 (m, 1H), 3.93 (m, 1H), 3.59 (m, 2H);  $\lambda^{MeOH}$  270 nm.

max 270 mm.

Anal. Calcd. for C<sub>12</sub>H<sub>16</sub>N<sub>4</sub>O<sub>5</sub>: C, 48.65; H, 5.44; N, 18.91. Found: C, 48.83; H, 5.54; N, 18.83.

 $\underbrace{(E)-5-(2-Carboxyetheny1) tubercidin (11)}_{NaOH solution was added 1.227 g (3.51 mM) 5-(2-methoxycarbonyl$ etheny1) tubercidin (7). After 3 hours at room temperature, thereaction mixture was acidified with 15% HCl to give, after filteringand drying at high vacuum, 1.030 g (3.06 mM, 87%) of a white powder:mp > 300°. HPLC (C-18 reverse phase, 0.01 M NH<sub>4</sub>H<sub>2</sub>PO<sub>4</sub>, acetonitrile,95:5, v/v) and TLC (silica gel; system A) showed a single component. $<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) <math>\delta$  8.38 (s, 1H), 8.32 (s, 1H), 7.98 (d, 1H, J = 16Hz), 6.46 (d, 1H, J = 16Hz), 6.20 (d, 1H, J = 6Hz), 4.47 (m, 1H), 4.18 (m, 1H), 4.00 (m, 1H), 3.71 (m, 2H).  $\lambda_{max}^{MeOH}$ : 313 nm, 261 nm.

Anal. Calcd. for C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>O<sub>6</sub>•H<sub>2</sub>O: C, 47.45; H, 5.12; N, 15.82. Found: C, 47.09; H, 4.94; N, 15.67.

(E)-5-(2-Bromoethenyl)tubercidin (12). A mixture of 170 mg

(0.50 mM) 5-(2-carboxyethenyl)tubercidin (11) and 100 mg (1.0 mM) potassium acetate in 7 mL dry DMF was heated on the steam bath to give a cloudy solution. The stirred mixture was cooled to room temperature and 90 mg (0.50 mM) N-bromosuccinimide in 1 mL dry DMF added dropwise and then stirred for 10 min. The reaction mixture was evaporated, taken up in methanol and evaporated with 3 g silica gel and chromatographed in a 2 cm diameter column of 200 g silica gel giving, after recrystallization from methanol, 50 mg (0.13 mM, 26%) of light-orange crystals: mp 164.5-167°C. HPLC (C-18 reverse phase; NH<sub>4</sub>H<sub>2</sub>PO<sub>4</sub>, acetonitrile, 83:17, v/v), and TLC (silica gel; system A) showed a single component. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  8.38 (s, 1H), 7.96 (s, 1H), 7.87 (d, 1H, J = 15Hz), 7.09 (d, 1H, J = 15Hz), 6.26 (d, 1H, J = 6Hz), 4.58 (m, 1H), 4.28 (m, 1H), 4.06 (m, 1H), 3.78 (m, 2H).  $\lambda_{max}^{MeOH}$ : 282 nm, 243 nm.

Anal. Calcd. for C<sub>13</sub>H<sub>15</sub>BrN<sub>4</sub>O<sub>4</sub>: C, 42.06; H, 4.07; Br, 21.53; N, 15.09. Found: C, 42.04; H, 4.17; Br, 21.56; N, 15.07.

 $\frac{5-(2-\text{Cyanoethyl})\text{ tubercidin (14).}}{100 \text{ mg, } 3.78 \text{ mmole}) \text{ was stirred at room temperature under 30 psig}}{1200 \text{ mg, } 3.78 \text{ mmole}) \text{ was stirred at room temperature under 30 psig}}{1200 \text{ mL MeOH with 80 mg 10% Pd/C for six hours.}} Chromatrography of the crude product, obtained from the filtrate after filtration and evaporation, on silica gel eluting with MeOH/CHCl<sub>3</sub> gave 5-(2-cyanoethyl)tubercidin (610 mg, 76%) mp. 223-224.5° (dec): <sup>1</sup>H NMR (d_6-DMSO) & 2.75 (t, 2H, J = 7Hz), 3.13 (t, 2H, J = 7Hz), 3.59 (m, 4H), 3.90 (m, 1H), 4.10 (m, 1H), 4.40 (m, 1H), 5.50 (m, 2H), 6.01 (d, 1H, J = 6Hz), 6.76 (s, 1H), 7.27 (s, 1H), 8.07 (s, 1H). TLC. Rf 0.41 (system B); <math>\lambda_{\text{max}}^{\text{H}_2\text{O}}$  276 nm (pH 5), 278 nm (pH 1.5), and 274 nm (pH 12).

Anal. Calcd. for C<sub>14</sub>H<sub>17</sub>N<sub>5</sub>O<sub>4</sub>: C, 52.66; H, 5.36; N, 21.93. Found: C, 52.43; H, 5.44; N, 21.71.

5-(2-Phenylethenyl)tubercidin (18). 5-Mercuritubercidin (4)

(5.25 g, 10.5 mM) was combined with styrene (5.7 mL, 50 mM) and 200 mL of methanolic 0.1 M Li<sub>2</sub>PdCl<sub>4</sub> solution (20 mM) and refluxed with stirring for 18 hours. The reaction mixture was then filtered. saturated with hydrogen sulfide, and refiltered and neutralized with conc. NH40H. The solution was evaporated with 10 g of silica gel and chromatographed on a 4 cm diameter column containing 300 g of silica gel eluting with a chloroform-methanol gradient. The chromatographic fractions containing the product were evaporated to a yellow oil, dissolved on 20 mL methanol and cooled overnight at 0° yielding 830 mg of yellow crystalline product. The mother liquor was reduced and yielded a second crop of 145 mg. Total yield: 975 mg (2.65 mM, 25.3%): mp 220.5-224°C. HPLC (C-18 reverse phase, 0.01 M  $NH_4H_2PO_4$ , acetonitrile, 7:3, v/v) and TLC (silica gel, system A) indicated a homogeneous product. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) (100MHz)  $\delta$  8.12 (s, 1H), 7.90 (s, 1H), 7.72-7.22 (m, 5H), 7.57 (d, 1H, J = 16.5Hz),7.04 (d, 1H, J = 16.5Hz), 6.12 (d, 1H, J = 6Hz), 4.47 (m, 1H), 4.14 (m, 1H), 3.95 (m, 1H), 3.64 (m, 2H). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)(360 MHz)  $\delta$ 8.08 (s, 1H, H-2), 7.85 (s, 1H, H-6), 7.67 (d, 2H, J = 7.45Hz, ortho-H), 7.36 (unsym., 2H, meta-H), 7.23 (t, 1H, J = 7.32Hz, para-H), 7.54 (d, 1H, J = 16.06Hz, H-1"[Table II]), 7.01 (d, 1H, J = 16.04Hz, H-2"), 6.08 (d, 1H, J = 6.2 Hz), 4.44 (m, 1H, H-2'), 4.12 (m, 1H, H-3'), 3.91 (m, 1H, H-4'), 3.53-3.70 (m, 2H, H-5').  $\lambda^{MeOH}$ : 310 nm, 268 nm.

Anal. Calcd. for C<sub>19</sub>H<sub>19</sub>N<sub>4</sub>O<sub>2</sub>: C, 62.12; H, 5.21; N, 15.25. Found: C, 61.85; H, 5.42; N, 15.09.

(E) and (Z)-5-(2-Buten-1-y1) tubercidin (13, 14). 5-Mercuri-

tubercidin (0.525 g, 1.0 mM), 1.01 mL (10 mN) 3-chloro-l-butene and 10 mL (1.0 mM) of a methanolic 0.1 M LiPdCl<sub>4</sub> solution were combined and stirred 48 hours at room temperature. The reaction mixture was saturated with H<sub>2</sub>S, filtered, neutralized with conc. NH<sub>4</sub>OH and evaporated with 5 g of silica gel. Chromatography on 200 g of silica gel eluting with a chloroform-methanol gradient gave, after recrystallization from methanol, 65 mg (0.20 mM, 20%) of white crystals: mp 187.5-190°, HPLC (C-18 reverse phase; 0.01 M  $NH_4H_2PO_1$ ; 85:15, v/v) and TLC (silica gel; system A) showed a single component. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  8.11 (s, 1H), 7.18 (s, 1H), 6.05 (d, 2H, J = 6Hz), 5.65 (narrow m, 2H), 4.49 (m, 1H), 4.15 (m, 2H), 3.68 (narrow m, 2H), 3.49 (narrow m, 2H), 1.69 (narrow m, 3H). The ratio of E to Z isomer was estimated to be 2:1 on the basis of the  $\lambda^{MeOH}$ : <sup>13</sup>C resonances. 275 nm. mas

Anal. Calcd. for C15H20N4O2: C, 56.24; H, 6.29; N, 17.49. Found: C, 56.52; H, 6.36; N, 17.62.

5-Iodotubercidin (15). 5-Mercuritubercidin (2)(1.575 g, 3.0 mM) and iodine (1.53 g) were dissolved with stirring in 50 mL DMF. After 18 hrs the DMF was removed by lyophilization and the brown oil chromatographed on silica gel (100 g) eluting with 16% MeOH/CHCl<sub>3</sub>. Fifteen mL fractions were collected. Fractions 8-45 were combined and evaporated to give a mixture of 23 and mercuric iodide. Most of the mercuric iodide could be eliminated by washing the solid first with acetone and then with methanol. Rechromatography on silica gel gave 23 (0.5486 g, 47%). Analytically pure 5-iodotubercidin, mp 190-191° (dec), could be obtained by recrystallization from methanol: <sup>1</sup>H NMR  $(6d-DMSO-D_2O) \delta 3.57$  (narrow m, 2H), 3.91 (m, 1H), 4.09 (m, 1H), 4.36 (m, 1H), 6.03 (d, 1H, J = 6.3Hz), 7.68 (s, 1H), 8.11 (s, 1H);  $\lambda_{\max}^{MeOH}$ : 282 nm ( $\epsilon$  9,030).

Anal. Calcd. for C<sub>11</sub>H<sub>13</sub>N<sub>4</sub>O<sub>4</sub>I: C, 33.69; H, 3.34; N, 14.29. Found: C, 33.85; H, 3.40; N, 14.18.

#### References

- J. Jaffe, in "Chemistry, Biology, and Clinical Uses of Nucleoside Analogs," A. Bloch, ed., <u>Annals of the New York of Science</u>, <u>255</u>, 306-316 (1975).
- J. J. Jaffe, H. M. Doremus, H. A. Dunsford, and E. Meymarian, <u>Am. J.</u> <u>Trop. Med. Hyg.</u>, <u>24</u>, 289 (1975).
- M. J. Schweickert and D. E. Bergstrom, "Preparation of C-5 Mercurated Tubercidin and C-5, C-6 Dimercurated Tubercidin," <u>J. Carbohydrates-</u> <u>Nucleosides - Nucleotides</u>, <u>5</u> (4), 285-296 (1978).
- 4. R. F. Heck, J. Am. Chem Soc., 91, 6707-6714 (1969).
- D. E. Bergstrom and M. K. Ogawa, "C-5 Substituted Pyrimidine Nucleosides II. Synthesis via Olefin Coupling to Organopalladium Intermediates Derived from Uridine and 2'-Deoxyuridine," J. Amer. Chem. Soc., 100, 8106 (1978).
- H. Kasai, Z. Ohashi, F. Harada, S. Nishimura, N. J. Oppenheimer, P. F. Crain, J. C. Liehr, D. L. von Minden, and J. A. McCloskey, <u>Biochemistry</u>, <u>14</u>, 4198 (1975).
- H. Kasai, K. Nishimura, R. D. Macfarlane, D. F. Torgerson, Z. Ohashi, T. A. McCloskey, H. J. Gross, and S. Nishimura, <u>J. Am. Chem. Soc.</u>, 98, 5044 (1976).
- 8. P. M. Henry, Tetrahedron Lett., 2285 (1968).
- 9. A. Schoenberg, I. Bartoletti, and R. F. Heck, <u>J. Org. Chem.</u>, <u>39</u>, 3318-3330 (1974).
- 10. R. C. Larock, <u>J. Org. Chem.</u>, <u>40</u>, 3237 (1975).
- 11. A. S. Jones, G. Verhelst, and R. T. Walker, Tetrahedron Lett., (1979).
- D. E. Bergstrom, J. L. Ruth, and P. Warwich, "C-5 Substituted Pyrimidine Nucleosides. 3. Reaction of Allylic Chlorides, Alcohols, and Acetates with Pyrimidine Nucleoside Derived Organopalladium Intermediates," manuscript submitted to J. Org. Chem.
- B. Brdar, D. B. Rifkin, and E. Reich, <u>J. Biol. Chem.</u>, <u>248</u>, 2397– 2408 (1973).
- 14. J. F. Henderson, A. R. P. Paterson, I. C. Caldwell, B. Paul, M. F. Chan, and K. F. Lau, <u>Cancer Chemother. Reports</u>, 3 (part 2), 71 (1972).
- 15. R. M. K. Dale, E. Martin, D. C. Livingston, and D. C. Ward, Biochemistry, 14, 2447-2457 (1975).
- 16. M-T. Chenon, R. J. Pugmire, D. M. Grant, R. P. Panzica, and L. B. Townsend, J. Am. Chem. Soc., 97, 4627-4636 (1975).

17. Sadtler Standard <sup>13</sup>C NMR Spectra; Sadtler Research Laboratories, Inc., 1976.

18. E. Kent Barefield, J. Chem. Educ., 50, 697 (1973).

۰.

U-WRAIR-SYN

# DISTRIBUTION LIST

The second se

5 copies	Director Walter Reed Army Institute of Research ATTN: SGRD-UWZ-C Walter Reed Army Medical Center Washington, DC 20012
4 copies	Commander US Army Medical Research and Development Command ATTN: SGRD-RMS Fort Detrick, Frederick, MD 21701
12 copies	Defense Technical Information Center (DTIC) ATTN: DTIC-DDA Cameron Station Alexandria, VA 22314
1 сору	Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20014
1 сору	Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234

